ImaginAb and Dainippon Seiki align on automated chemistry systems

ImaginAb and Dainippon Seiki have reached a technology agreement pertaining to the development of automated chemistry systems for fluorination of proteins and peptides for diagnostic imaging with PET.

The collaboration between Inglewood, Calif.-based ImaginAb and Kyoto, Japan-based Dainippon Seiki will develop high-throughput fluorination systems suitable for both preclinical and, eventually, clinical use.

"We have seen a significant increase in the interest level in novel peptides and biologics for diagnostic imaging and believe in the commercial importance of automated fluorine chemistry to drive this industry ahead,” said Masayoshi Sugihara, president of Dainippon Seiki.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.